Bavarian Nordic soars on FDA vax OK

Shares of Bavarian Nordic jumped more than 20 percent this morning after the company reported that the FDA had raised a green flag for the production and delivery of its smallpox vaccine Imvamune. Analysts cheered the move as a major event for the biopharma company. "This represents a transformational step in the company lifecycle of Bavarian Nordic from being a developmental, R&D focused company to an order producing pharmaceutical business," S&P says in a note. Bavarian release | Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.